J&J told Reuters it would not comment on its enrolment beyond a Friday statement that said the trial had closed. But the move has raised questions, and sparked disappointment, for some in Latin America, according to interviews with a dozen researchers, government officials and disease experts. J&J told Reuters in September that those hosting trials would have priority for vaccine supply. "Countries in Latin America, as they are establishing trial sites, need to pressure for these deals when they are negotiating with the industry. J&J in the statement issued on Friday expressed "its thanks to all participants, trial sites and health care professionals involved in the ENSEMBLE study."

Source: bd News24 December 22, 2020 05:26 UTC